Compounding pharmacy defeats, for now, Eli Lilly false advertising claims
Eli Lilly & Co.’s struggle to put the genie back in the tirzepatide bottle following an almost two-year long, FDA-declared shortage of the Mounjaro and Zepbound active ingredient continued this week,...To view the full article, register now.
Already a subscriber? Click here to view full article